Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Marschalek R . Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011; 152: 141–154.

    Article  CAS  PubMed  Google Scholar 

  2. Cox MC, Panetta P, Lo-Coco F, Del Poeta G, Venditti A, Maurillo L et al. Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. Am J Clin Pathol 2004; 122: 298–306.

    Article  CAS  PubMed  Google Scholar 

  3. Zhang Y, Chen A, Yan XM, Huang G . Disordered epigenetic regulation in MLL-related leukemia. Int J Hematol 2012; 96: 428–437.

    Article  CAS  PubMed  Google Scholar 

  4. Slany RK . The molecular biology of mixed lineage leukemia. Haematologica 2009; 94: 984–993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. So CW, Lin M, Ayton PM, Chen EH, Cleary ML . Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 2003; 4: 99–110.

    Article  CAS  PubMed  Google Scholar 

  6. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML . The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005; 123: 207–218.

    Article  CAS  PubMed  Google Scholar 

  7. Grembecka J, Belcher AM, Hartley T, Cierpicki T . Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J Biol Chem 2010; 285: 40690–40698.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shi A, Murai MJ, He S, Lund G, Hartley T, Purohit T et al. Structural insights into inhibition of the bivalent menin–MLL interaction by small molecules in leukemia. Blood 2012; 120: 4461–4469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S et al. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood 2014; 124: 263–272.

    Article  CAS  PubMed  Google Scholar 

  10. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41–47.

    Article  CAS  PubMed  Google Scholar 

  11. Wang QF, Wu G, Mi S, He F, Wu J, Dong J et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011; 117: 6895–6905.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011; 20: 66–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006; 20: 2147–2154.

    Article  CAS  PubMed  Google Scholar 

  14. Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J et al. Pharmacologic inhibition of the Menin–MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell 2015; 27: 589–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ et al. Menin–MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012; 8: 277–284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Institute of Health grant R01 (1R01CA160467) to JG, a Leukemia and Lymphoma Society (LLS) TRP grant (6116–12) and the LLS Therapy Acceleration Program to JG, LLS Scholar (1215–14) to JG, American Cancer Society grants (RSG-11-082-01-DMC to TC and RSG-13-130-01-CDD to JG) and the Department of Pathology, the University of Michigan.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Grembecka.

Ethics declarations

Competing interests

Drs Grembecka and Cierpicki received research support from Kura Oncology. They are also receiving compensation as members of the scientific advisory board of Kura Oncology, and they have an equity ownership in the company. The remaining authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, S., Malik, B., Borkin, D. et al. Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner. Leukemia 30, 508–513 (2016). https://doi.org/10.1038/leu.2015.144

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.144

This article is cited by

Search

Quick links